基本信息
浏览量:0
职业迁徙
个人简介
Research interests
Cancer is a very heterogeneous disease, making morphological classification and management of patients a significant challenge. Despite great advances it remains difficult to predict which patients are at risk of their disease returning (recurrence), spreading (metastasis) or which patients will gain most benefit to specific therapies. There has therefore been a concerted effort to supplement the morphological classification of disease with molecular parameters that can provide a clearer appreciation for this complexity and better predict tumour behaviour. This ideology has driven significant advancements in the field of molecular pathology research.
Peter's research program embraces these advances in technology to help better understand mechanisms of disease development and progression and help improve the molecular aspects of diagnosis and patient management. Themes of research involve 1) invasive lobular carcinoma of the breast, 2) familial breast cancer, and 3) lung cancer.
Invasive Lobular Carcinoma (ILC) is the most commonly diagnosed ‘special’ morphological type of breast cancer, comprising up to 15% of all cases. They exhibit a very characteristic set of clinical, pathological and biological properties, including a progressive decline in survival, an infiltrative pattern of growth and down regulation of cell adhesion molecule, E-cadherin. Morphological variants exist that are associated with a worse outcome compared to the classic type. A large component of Peter's research focuses on aspects of this specific disease subtype, including understanding molecular determinants that predict tumour behaviour, and mechanisms of invasion and metastasis.
Family history is a significant risk factor for the development of breast cancer. For some individuals and their families, the genetic component of this risk is well understood and attributed to pathogenic germline variants in moderate-high risk genes (e.g. BRCA1, BRCA2, PALB2, TP53, ATM, CHEK2). For most individuals the underlying genetic risk is unknown. We have been using whole genome sequencing of germline and matched tumour DNA to characterise somatic mutation signatures present in tumours from high risk individuals. These approaches are providing insight into the mechanisms driving tumourigenesis in familial breast cancers and also therapeutic strategies.
Endobronchial ultrasound transbronchial needle aspiration (EBUS-TBNA) sampling of lymph nodes is an important procedure to make a diagnosis of Lung cancer, particulalry in patients presenting with advanced, inoperable disease. Next generation sequencing is an important component of diagnostic practice and therapeutic decision making for lung cancer patients. Our program of work is focused on optimising sequencing approaches from small diagnostic aspirate samples yielded by EBUS TBNA.
Cancer is a very heterogeneous disease, making morphological classification and management of patients a significant challenge. Despite great advances it remains difficult to predict which patients are at risk of their disease returning (recurrence), spreading (metastasis) or which patients will gain most benefit to specific therapies. There has therefore been a concerted effort to supplement the morphological classification of disease with molecular parameters that can provide a clearer appreciation for this complexity and better predict tumour behaviour. This ideology has driven significant advancements in the field of molecular pathology research.
Peter's research program embraces these advances in technology to help better understand mechanisms of disease development and progression and help improve the molecular aspects of diagnosis and patient management. Themes of research involve 1) invasive lobular carcinoma of the breast, 2) familial breast cancer, and 3) lung cancer.
Invasive Lobular Carcinoma (ILC) is the most commonly diagnosed ‘special’ morphological type of breast cancer, comprising up to 15% of all cases. They exhibit a very characteristic set of clinical, pathological and biological properties, including a progressive decline in survival, an infiltrative pattern of growth and down regulation of cell adhesion molecule, E-cadherin. Morphological variants exist that are associated with a worse outcome compared to the classic type. A large component of Peter's research focuses on aspects of this specific disease subtype, including understanding molecular determinants that predict tumour behaviour, and mechanisms of invasion and metastasis.
Family history is a significant risk factor for the development of breast cancer. For some individuals and their families, the genetic component of this risk is well understood and attributed to pathogenic germline variants in moderate-high risk genes (e.g. BRCA1, BRCA2, PALB2, TP53, ATM, CHEK2). For most individuals the underlying genetic risk is unknown. We have been using whole genome sequencing of germline and matched tumour DNA to characterise somatic mutation signatures present in tumours from high risk individuals. These approaches are providing insight into the mechanisms driving tumourigenesis in familial breast cancers and also therapeutic strategies.
Endobronchial ultrasound transbronchial needle aspiration (EBUS-TBNA) sampling of lymph nodes is an important procedure to make a diagnosis of Lung cancer, particulalry in patients presenting with advanced, inoperable disease. Next generation sequencing is an important component of diagnostic practice and therapeutic decision making for lung cancer patients. Our program of work is focused on optimising sequencing approaches from small diagnostic aspirate samples yielded by EBUS TBNA.
研究兴趣
论文共 418 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Vaibhavi Joshi, Andrew Stacey, Yufan Feng,Priyakshi Kalita-de Croft,Pascal H. G. Duijf,Peter T. Simpson,Sunil R. Lakhani,Amy E. McCart Reed
The journal of pathology Clinical researchno. 2 (2024)
DALTON TRANSACTIONSno. 7 (2024): 3407-3413
David Fielding,Vanessa Lakis,Andrew J. Dalley,Haarika Chittoory,Felicity Newell,Lambros T. Koufariotis,Ann-Marie Patch,Stephen Kazakoff,Farzad Bashirzadeh,Jung Hwa Son,Kimberley Ryan,Daniel Steinfort,Jonathan P. Williamson,Michael Bint,Carl Pahoff,Phan Tien Nguyen,Scott Twaddell,David Arnold,Christopher Grainge, Andrew Pattison,David Fairbairn, Shailendra Gune, Jemma Christie,Oliver Holmes,Conrad Leonard,Scott Wood,John V. Pearson,Sunil R. Lakhani,Nicola Waddell,Peter T. Simpson,Katia Nones
Cancersno. 4 (2024)
Kevin M. Koo, Malcom Lim,Peter Simpson,Sunil Lakhani,Matthew Roberts, Mostafa Masud, Simon Puttick, Stephen Rose
ChemNanoMat (2024)
Vaibhavi Joshi,Kate Beecher,Malcolm Lim, Andrew Stacey, Yufan Feng,Parmjit S. Jat,Pascal H. G. Duijf,Peter T. Simpson,Sunil R. Lakhani,Amy E. McCart Reed
International journal of molecular sciencesno. 7 (2024): 3976-3976
Cancer Researchno. 9_Supplement (2024): PO3-15
Andrew Causer,Xiao Tan,Xuehan Lu,Philip Moseley, Min Teoh,Margaret McGrath,Taehyun Kim,Peter Simpson,Christopher Perry,Ian Frazer,Benedict Panizza,Rahul Ladwa,Quan Nguyen, Jazmina L Gonzalez-Cruz
biorxiv(2023)
Christine Desmedt,Ha-Linh Nguyen,Tatjana Geukens,Marion Maetens,Samuel Aparicio,Ayse Bassez,Åke Borg,Jane B. Brock,Annegien Broeks,Carlos Caldas,Fátima Cardoso,Maxim De Schepper,Mauro Delorenzi,C.A. Drukker,Annuska M. Glas, Andrew Green,Edoardo Isnaldi,Jórunn E. Eyfjörd,Hazem Khout,Stian Knappskog,Savitri Krishnamurthy,Sunil R. Lakhani,Anita Langerød,John W.M. Martens,Amy E. McCart Reed,Leigh C. Murphy,Stefan Naulaerts,Serena Nik-Zainal,Ines Nevelsteen,Patrick Neven,Martine Piccart‐Gebhart,Coralie Poncet,Kevin Punie,Colin A. Purdie,Emad A. Rakha,Andrea L. Richardson,Ejt Rutgers,Anne Vincent‐Salomon,Peter T. Simpson,Marjanka K. Schmidt,Christos Sotiriou,Paul N. Span,Karsoon Tan,Alastair Thompson,Stefania Tommasi,Karen Van Baelen,M. van de Vijver,Steven Van Laere,Laura J. van ‘t Veer,Giuseppe Viale,Alain Viari,Hanne Vos,Anke Witteveen,Hans Wildiers,Giuseppe Floris,Abhishek D. Garg,Ann Smeets,Diether Lambrechts,Elia Biganzoli,François Richard
Research Square (Research Square) (2023)
Levi Waldron,Shuji Ogino,Yujin Hoshida,Kaori Shima,Amy E. McCart Reed,Peter T. Simpson,Yoshifumi Baba,Katsuhiko Nosho,Nicola Segata,Ana Cristina Vargas,Margaret C. Cummings,Sunil R. Lakhani,Gregory J. Kirkner,Edward Giovannucci,John Quackenbush,Todd R. Golub,Charles S. Fuchs,Giovanni Parmigiani,Curtis Huttenhower
pubmed(2023)
Molecular pharmaceuticsno. 12 (2023): 6169-6183
加载更多
作者统计
#Papers: 418
#Citation: 19189
H-Index: 68
G-Index: 127
Sociability: 8
Diversity: 0
Activity: 2
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn